Enhancing the Standard of Care: The Breast Surgery Collaborative Community Proposes Streamlined FDA Patient Decision Checklist

ARLINGTON HEIGHTS, IL — In a significant move toward refining the informed consent process for patients undergoing breast implant surgery, the Breast Surgery Collaborative Community (BSCC) has officially submitted a proposal to the U.S. Food and Drug Administration (FDA) to update the current Patient Decision Checklist. This initiative marks a milestone in the ongoing dialogue between regulatory bodies, medical practitioners, and patient advocates, aiming to replace overly complex documentation with a tool that is both clinically practical and truly patient-centric.

The proposal, now open for public comment on the FDA docket, represents the culmination of a consensus-based effort designed to rectify long-standing criticisms regarding the accessibility of information for those considering breast augmentation or reconstruction.

The Genesis of the Initiative: Addressing a Regulatory Gap

The 2022 Implementation and Initial Hurdles

When the FDA introduced the mandatory Patient Decision Checklist in 2022, the intent was to provide a robust, standardized mechanism for ensuring that patients were fully informed of the risks and benefits associated with breast implants. While the regulatory spirit of the mandate was widely praised by medical societies, the practical application in the exam room faced immediate headwinds.

Within months of implementation, both surgeons and patients identified significant friction points. Clinicians reported that the document’s length and repetitive nature often detracted from, rather than enhanced, the quality of the patient-physician dialogue. For patients, the document was frequently perceived as a dense legalistic hurdle rather than an educational tool. The "check-the-box" nature of the original document led to concerns that it was serving as a mere administrative checkbox for compliance, potentially overshadowing the nuanced, individualized counseling required for safe surgical outcomes.

The Shift Toward "Patient-Friendly" Documentation

Recognizing these concerns, the BSCC—a coalition comprised of board-certified plastic surgeons, patient advocates, and industry representatives—initiated a comprehensive review process. The objective was clear: transform the checklist into a document that encourages, rather than replaces, the critical "shared decision-making" process.

The proposed update aims to distill the essential safety information into a format that is more readable, concise, and applicable to real-world clinical consultations. By streamlining the language, the BSCC believes the updated checklist will ensure that patients remain focused on the most pertinent safety data, leading to a more empowered and well-informed surgical experience.

Chronology of the Collaborative Effort

The journey toward this proposed revision has been defined by a multidisciplinary approach, prioritizing the voices of those most impacted by the surgery.

2022: The FDA implements the mandatory Patient Decision Checklist for all breast implant procedures.
Late 2022 – Early 2023: Early feedback from clinical settings highlights the need for a more concise tool. Patient advocates express concerns that the original document is too complex for the average patient to absorb effectively during a standard consultation.
Mid-2023: The BSCC formally convenes a task force dedicated to the revision of the document, ensuring participation from diverse stakeholders, including patient advocates from the Breast Implant Safety Alliance (BISA) and Young Survival Coalition.
2024: The BSCC engages in multiple rounds of consensus-building, iterating on draft versions of the checklist to balance regulatory requirements with clinical practicality.
Late 2024: The final proposed draft is submitted to the FDA public docket, opening the floor for national stakeholder review.

Supporting Data and the Philosophy of Shared Decision-Making

Why "Shared Decision-Making" Matters

At the heart of the BSCC’s mission is the concept of shared decision-making. Medical literature consistently demonstrates that when patients are actively involved in the decision-making process—and when they fully understand the risks, such as Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) or systemic symptoms—satisfaction rates increase and post-operative anxiety decreases.

The BSCC argues that the current, lengthy checklist often creates a "cognitive overload" that may actually impede a patient’s ability to process the information. By providing a streamlined version, the surgeon can facilitate a more fluid, organic conversation, ensuring that the patient’s specific goals and risk tolerance are the center of the surgical plan.

The Composition of the BSCC

The strength of this proposal lies in the diversity of the community that authored it. The membership is not exclusively surgical; it includes a robust contingent of patient advocates who have been instrumental in ensuring that the patient perspective remains the guiding star of the document.

The group includes representatives from:

The American Society of Plastic Surgeons (ASPS)
The Aesthetic Society
The Plastic Surgery Foundation (PSF)
The Breast Implant Safety Alliance (BISA)
Young Survival Coalition
FORCE: Facing Our Risk of Cancer Empowered

By including industry representatives (non-voting) alongside surgeons and patients, the BSCC has ensured that the proposed updates remain technically accurate regarding device specifications while staying grounded in the lived experience of the patient.

Breast Surgery Collaborative Community Invites Public Comment on Updated FDA Patient Decision Checklist

Official Responses and Regulatory Implications

The FDA’s Role

The FDA’s collaborative community framework is designed to allow for precisely this type of "bottom-up" innovation. By allowing professional societies and patient advocates to propose updates based on empirical data from the field, the FDA ensures that its regulations stay relevant to the evolving landscape of medical technology and patient needs.

While the FDA has yet to officially ratify the proposed changes, the agency’s invitation for public comment signifies a willingness to re-evaluate the 2022 mandate. The submission to the public docket is not merely a formality; it is a critical regulatory step that allows the FDA to gauge the consensus of the broader medical and patient community.

Industry Perspectives

Manufacturers of breast implants, including Mentor Worldwide LLC, Establishment Labs, and Sientra, have participated in the discussions as non-voting members. Their role has been to provide technical data regarding device labeling and regulatory feasibility. Their participation ensures that the new checklist remains compliant with global regulatory standards while making the necessary concessions for clarity and brevity.

Implications for the Future of Plastic Surgery

The proposed revisions carry significant implications for both the practice of plastic surgery and the broader landscape of medical device regulation.

Impact on the Consultation Process

For the average board-certified plastic surgeon, the adoption of this updated checklist would represent a return to more effective patient education. Rather than spending significant time navigating a rigid, lengthy document, the surgeon can utilize the revised checklist as a navigational aid, highlighting the most critical safety information while leaving space for the unique, patient-specific discussion that is the hallmark of ethical plastic surgery.

A Template for Future Regulations

The BSCC’s approach serves as a potential blueprint for other medical specialties. The challenges faced in the breast surgery space—balancing complex risk information with the need for patient comprehension—are common across many areas of medicine. If this collaborative model succeeds in creating a more efficient and effective checklist, it may provide a roadmap for other collaborative communities to address similar issues in fields like orthopedics, cardiology, or oncology.

How to Participate: A Call for Public Comment

The BSCC is strongly encouraging all interested parties—patients, surgeons, nursing staff, and patient advocacy groups—to review the proposed checklist and provide feedback via the official FDA public docket.

Submission Details:

Deadline: December 1, 2026
Portal: https://www.regulations.gov/comment/FDA-2019-D-4467-1386
Tracking Number: You must include the reference number mt7-xgl2-2crx in your submission to ensure the FDA correctly associates your comment with the BSCC proposal.

Public input is vital to this process. The BSCC intends to use the feedback gathered during this period to make final adjustments to the document before it is formally finalized for implementation.

Conclusion: A Commitment to Continuous Improvement

The proposal submitted by the Breast Surgery Collaborative Community is a testament to the power of a multidisciplinary, transparent, and patient-first approach to medical regulation. By acknowledging the flaws in the current system and working collectively to correct them, the BSCC has demonstrated that the goal of patient safety is best served through ongoing, collaborative refinement.

As the industry looks toward the December 2026 deadline, the focus remains on a single, shared objective: creating a surgical environment where patients are not only protected by regulation but are also empowered by clear, actionable, and meaningful information. The proposed update to the Patient Decision Checklist is a vital step toward that reality, promising a more efficient and supportive experience for everyone involved in the breast surgery process.